JAGX Key Statistics, Chart & Performance
The current stock price of JAGX is 1.13 USD. In the past month the price increased by 4.63%. In the past year, price decreased by -95.48%.
JAGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About JAGX
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Company Info
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Phone: 14153718300
JAGUAR HEALTH INC / JAGX FAQ
What does JAGX do?
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
What is the stock price of JAGUAR HEALTH INC today?
The current stock price of JAGX is 1.13 USD. The price increased by 9.71% in the last trading session.
Does JAGX stock pay dividends?
JAGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of JAGX stock?
JAGX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is JAGUAR HEALTH INC (JAGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on JAGX.
Can you provide the upcoming earnings date for JAGUAR HEALTH INC?
JAGUAR HEALTH INC (JAGX) will report earnings on 2026-03-30, after the market close.
What is the Short Interest ratio of JAGUAR HEALTH INC (JAGX) stock?
The outstanding short interest for JAGUAR HEALTH INC (JAGX) is 7.93% of its float.
JAGX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to JAGX. When comparing the yearly performance of all stocks, JAGX is a bad performer in the overall market: 98.07% of all stocks are doing better.
JAGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JAGX. JAGX may be in some trouble as it scores bad on both profitability and health.
JAGX Financial Highlights
Over the last trailing twelve months JAGX reported a non-GAAP Earnings per Share(EPS) of -33.58. The EPS decreased by -19.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.45% | ||
| ROE | -716.07% | ||
| Debt/Equity | 1.36 |
JAGX Forecast & Estimates
7 analysts have analysed JAGX and the average price target is 16.32 USD. This implies a price increase of 1344.25% is expected in the next year compared to the current price of 1.13.
For the next year, analysts expect an EPS growth of 89.56% and a revenue growth 24.03% for JAGX